BioNTech has successfully tested a cancer vaccine.
.in_text_content_22 { width: 300px; height: 600px; } @media(min-width: 600px) { .in_text_content_22 { width: 580px; height: 400px; } }
Ugur Sahin, founder of the German company BionTech, famous for developing a vaccine against coronavirus, said that they are working on a vaccine for cancer.
He said in an interview with the Bild am Sonntag newspaper that the results of research conducted in this area will be known in 2025-2029.
They hope that the first personalized mRNA-based cancer vaccines could be approved before 2030.
We take blood and tumor samples from the patient, and four weeks later we administer an individual vaccine… Ideally, this is not 100, but tens of thousands of patients a year,” said Ugur Sahin, one of the founders of BioNTech.
In October, the company announced results from the first clinical trial of a combination of an mRNA cancer vaccine and CAR T cell therapy (creating immune cells to treat cancer). Tumors stopped growing in almost all patients and shrank by almost two-thirds.
This approach can force the immune system to specifically seek out and destroy tumors with an army of specialized warriors, Sahin said.
According to him, the strategy of the future is combination therapy of different approaches.
I believe that over the next few years, ADCS (Antibody-Drug Conjugates) will increasingly be used as a targeted chemotherapy, rather than classical chemotherapy, for many oncology indications.
The spouses of German doctors and research scientists of Turkish origin, Ugur Sahin and Ozlem Tureci, are the founders and owners of the BioNTech company, on the basis of which the BioNTech coronavirus vaccine, Pfizer, was developed and launched into production.
Source: Racurs
I am David Wyatt, a professional writer and journalist for Buna Times. I specialize in the world section of news coverage, where I bring to light stories and issues that affect us globally. As a graduate of Journalism, I have always had the passion to spread knowledge through writing.